Personalized care in uterine cancer. - Wikidata - awgldk - TriplyDB

Personalized care in uterine cancer.

Personalized care in uterine cancer.

http://www.wikidata.org/entity/Q37006856

about

Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis.

P2860

Q35958280-49708DCC-C015-42BE-8351-421C2F32E555

P2860

Personalized care in uterine cancer.

http://www.wikidata.org/entity/Q37006856

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Personalized care in uterine cancer.

@en

Personalized care in uterine cancer.

@nl

type

label

Personalized care in uterine cancer.

@en

Personalized care in uterine cancer.

@nl

prefLabel

Personalized care in uterine cancer.

@en

Personalized care in uterine cancer.

@nl

P1433

Q37006856-B96C9C51-D3EB-424A-8613-91BB17CB1BB1

P1476

Q37006856-8C34C9F7-9C1E-4D33-B55C-E232B78875E8

P2093

Q37006856-16E7308B-A008-4D0C-8222-27F8E53A8BF0

Q37006856-AFA4AA44-14C2-4676-9489-33101F71AA7B

P2860

Q37006856-00F71C13-D702-4442-A51D-15E307E0D609

Q37006856-03B5E93F-FEC7-430F-BF32-76D0E9EA4B55

Q37006856-040DAF64-FA33-4EEA-809C-EE062D4F206E

Q37006856-0DD53019-4CBE-4A6D-AA0A-B1F4EB81646C

Q37006856-142B7D43-7DAE-42B7-81CB-2849ED23D23C

Q37006856-175A2986-E121-4BA6-8A27-C3F6E3042395

Q37006856-1779CC56-8596-45AA-BA49-A2118EE92D97

Q37006856-17D43D5E-3921-4ACB-ABA5-18AD1521DAC8

Q37006856-1C8489E5-583F-457B-AE2E-9C7A45B41C43

Q37006856-32FA9F36-6D60-454E-AB91-7C4A0A8C2D46

P304

Q37006856-F4031966-DDB9-48B6-91B5-978D916AE229

P31

Q37006856-25CAFAE2-1073-4243-A7E8-62CE2E565524

P433

Q37006856-B2602148-4DC2-416A-B9F2-3F4E08AEFE85

P478

Q37006856-4DB4C38C-3DD9-486C-BBBB-48338BF63C47

P577

Q37006856-1E4339CC-8B25-46C0-B8EB-B2E8DC13C8CC

P698

Q37006856-6B45FCA1-5652-4C70-A5F4-26BA985E5CC6

P932

Q37006856-8A727BE2-9EAC-41B3-A715-3D7B64DED1FD

P1433

Clinical advances in hematology & oncology : H & O

P1476

Personalized care in uterine cancer

@en

P2093

David A Iglesias

http://www.w3.org/2001/XMLSchema#string

Diane C Bodurka

http://www.w3.org/2001/XMLSchema#string

P2860

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma.

Molecular profiling of endometrial malignancies.

P304

797-805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23271352

http://www.w3.org/2001/XMLSchema#string

P932

4908823

http://www.w3.org/2001/XMLSchema#string